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Background/Aims: Esophageal eosinophilia occurs in many conditions, including eosinophilic esophagitis (EoE) and proton pump 
inhibitor-responsive esophageal eosinophilia (PPI-REE), which have been increasingly recognized in Western countries. There have 
been only a few reports in Korea. Here, we evaluated the clinical and endoscopic characteristics of patients with esophageal eosino-
philia from our experience. 
Methods: Nineteen patients were diagnosed with esophageal eosinophilia based on typical symptoms, endoscopic features, esoph-
ageal eosinophilia with ≥15 eosinophils/high power field, and response to medication by PPI. Symptoms, endoscopic and patho-
logical findings were evaluated.
Results: Of the 19 patients, 2 patients were diagnosed with EoE, 7 patients were diagnosed with PPI-REE, and 10 patients were un-
determined due to loss to follow-up. Among these 19 patients, dysphagia was present in 11, and heartburn, dyspepsia and reflux 
in 8. Sixteen patients had common endoscopic features, such as longitudinal furrows, concentric rings, strictures, and white plaques; 
however, 3 patients had normal findings. Nine patients underwent endoscopy at the time of follow-up. Two patients had complete 
resolution, and 3 had partial resolution. However, 4 patients showed no endoscopic changes. All patients showed symptom 
improvements. 
Conclusions: The clinical and endoscopic characteristics of both groups in Korea were undistinguishable. However, after treatment, 
endoscopic findings were different between the two groups. Large-scale studies are warranted to confirm our findings. (Korean J 
Gastroenterol 2018;72:10-14)
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INTRODUCTION
Esophageal eosinophilia occurs in many conditions. It is 
primarily caused by chronic eosinophilic infiltration of esoph-
ageal epithelium. Eosinophilic esophagitis (EoE), proton pump 
inhibitor-responsive esophageal eosinophilia (PPI-REE), and 
gastroesophageal reflux disease are common diseases of 
esophageal eosinophilia. EoE was first described in 1978, 
and PPI-REE was a newly acknowledged disease in 2006, 
which was distinct from EoE. PPI-REE is diagnosed when pa-
tients have typical esophageal symptoms and histologic fea-
tures of esophageal eosinophilia, but show symptomatic and 
histologic response to a course of PPI therapy; since this time, 
the entity is considered distinct from EoE.1,2 EoE is diagnosed 
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in the absence of other causes of esophageal eosinophilia 
and unresponsiveness PPI therapy.3
In a previous Western study, PPI-REE was about one-third 
of esophageal eosinophilia.4 Other studies demonstrated 
that a wide range 39-75% of adults with esophageal eosino-
philia have PPI-REE.5,6 Only a few studies regarding PPI-REE 
have been reported in Asian populations. A Japanese case 
series of 12 patients with esophageal eosinophilia reported 
that after PPI treatment, 2 patients (28.6%) were diagnosed 
with EoE, and 5 patients (71.4%) were diagnosed with 
PPI-REE.7 In these studies, clinical, endoscopic, and histo-
logical features could not distinguish the two groups apart at 
baseline before PPI. These findings emphasize the necessity 
of a PPI trial as per the current guidelines to accurately diag-
nose EoE. 
 Dysphagia is the most common symptom with esophageal 
eosinophilia. Heartburn or dyspepsia has also been reported. 
Esophageal eosinophilia is more frequently observed in 
males, and the average age of onset is between the twenties 
and forties. Endoscopic features include longitudinal mu-
cosal furrows, rings or circular corrugations, and long stric-
tures in the body of the esophagus.8
Esophageal eosinophilia is an immune/antigen-mediated 
disease, in which food or environmental antigens stimulate 
an inflammatory response. It has frequently been associated 
with allergies, although the causal relationship has yet to be 
determined. Despite an increased understanding of in-
flammatory pathogenesis, changes of endoscopic findings, 
following the treatment of esophageal eosinophilia, has not 
been clearly defined to date. There has recently been an in-
crease in the incidence and prevalence of esophageal eosi-
nophilia due to the increasing recognition of EoE and 
PPI-REE;9,10 however, there have been very few reports re-
garding these in Korea. Hence, we aimed to investigate the 
clinicopathologic characteristics of patients with EoE and 
PPI-REE from a single center’s experience.
SUBJECTS AND METHODS
We reviewed 19 patients with clinically, endoscopically, 
and histologically confirmed esophageal eosinophilia at a 
single university hospital between April 2007 and September 
2016. Patients were diagnosed with EoE if they met the fol-
lowing criteria: (1) having symptoms related to esophageal 
dysfunction; (2) mucosal eosinophilia in a esophageal biopsy 
with at least 15 eosinophils per high power field, which per-
sisted even after a PPI therapeutic regimen; and (3) absence 
of other causes of esophageal eosinophilia. Patients were di-
agnosed with PPI-REE if they had esophageal symptoms and 
histologic features of esophageal eosinophilia, and a reso-
lution of symptoms and histologic features after an 8-week 
course of a PPI therapeutic regimen.11
We checked the baseline characteristics, including sex, 
age, symptoms, and endoscopic findings. The typical symp-
toms that included dysphagia, heartburn, dyspepsia, and re-
flux were noted. We suspected esophageal eosinophilia 
when endoscopic findings showed longitudinal furrows, con-
centric rings, white plaque, and stricture. When esophageal 
eosinophilia was suspected, we obtained two to four biopsies 
to get sufficient specimens. 
Treatment of esophageal eosinophilia consisted of PPI and 
or inhaled steroid (fluticasone propionate) for 8 weeks. After 
treatment, a follow-up endoscopy with esophageal biopsy 
and assessment of symptom change were performed. 
This study was approved by the Institutional Review Board 
of Gangnam Severance Hospital, Yonsei University College of 
Medicine.
RESULTS
Of the 19 patients (14 men and 5 women; mean age, 44.3 
years) with esophageal eosinophilia, 10 did not undergo a fol-
low-up endoscopy after treatment due to loss of follow-up. 
Two of 9 patients that underwent follow-up endoscopy were 
diagnosed with EoE and 7 patients were diagnosed with 
PPI-REE. The baseline characteristics, symptoms, and endo-
scopic findings are summarized in Table 1. 
The mean age of patients with EoE was 44 years (range, 33 
to 64), and 1 patient was male. Both EoE patients had symp-
toms with dysphagia, each patient had heartburn and reflux. 
One of 2 EoE patients had endoscopic findings with both of 
longitudinal furrows and concentric rings, but the other 1 pa-
tient had a normal endoscopic finding, even though he had 
typical esophageal symptoms. The mean age of patients with 
PPI-REE was 35 years (range, 19 to 56) and all 7 patients 
were males. Among the 7 PPI-REE patients, dysphagia was 
present in 4, heartburn in 2, and reflux in 1. Six of 7 PPI-REE 
patients had endoscopic findings with longitudinal furrows, 
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Table 1. Baseline Characteristics
EOE PPI-REE Undetermined
N 2 7 10
Age, median (range) 44 (33-64) 35 (19-56) 50 (30-70)
Gender, male 1 7 6
Symptom
Dysphagia 2 4 5
Heartburn 1 2 3
Dyspepsia 0 0 3
Reflux 1 1 1
Endoscopic findings
Longitudinal furrows 1 6 6
Concentric rings 1 4 6
Stricture 0 1 0
White plaque 0 1 1
Normal finding 1 0 2
EOE, eosinophilic esophagitis; PPI-REE, proton pump inhibitor-responsive esophageal eosinophilia; N, Numbers.
4 had concentric rings, 1 had a stricture, and 1 had white 
plaques. All patients took a standard dose of PPI initially. Two 
EoE patients showed no symptom improvement within about 
8 weeks after PPI medication. Hence, they were administered 
an inhaled corticosteroid. Seven PPI-REE patients showed 
symptom improvement within the 8-week period after PPI 
medication. Nine patients underwent endoscopy at the time 
of follow-up, but 10 patients were loss to follow-up. Two pa-
tients had complete resolution of endoscopic findings and 3 
had partial resolution. However, 3 patients showed no endo-
scopic improvement and 1 patient, which had previous nor-
mal endoscopic finding, maintained normal endoscopic 
finding. Fig. 1 showed diverse alterations of endoscopic find-
ings after treatment. Eight of 9 patients with EoE and PPI-REE 
showed histologic improvement, but 1 patient did not show 
any improvement. All patients with EoE and PPI-REE showed 
symptom improvement. 
DISCUSSION
Our understanding of esophageal eosinophilia with EoE 
have substantially advanced over the past 2 decades. 
However, acknowledgement of PPI-REE as a distinct entity 
from EoE has been a recent phenomenon. EoE and PPI-REE 
are now commonly encountered due to upper gastro-
intestinal symptoms and morbidity in both children and 
adults.3,12
In our study, we reviewed a total of 19 patients that in-
cluded 9 patients with EoE or PPI-REE and 10 patients with 
undetermined esophageal eosinophilia. Their clinicopatho-
logic characteristics with the treatment outcomes were in-
vestigated and compared to previous studies. 
The age and gender ratios in this study were similar to 
those in previous studies from both Western and Asian 
countries.13,14 However, reasons for male preponderance of 
esophageal eosinophilia has yet to be clarified. Dysphagia, 
the most frequently reported symptom of esophageal eosi-
nophilia in both Asian and Western countries, was found in 
about 50% of patients.14  The main symptom was dysphagia, 
which was more than 50% of esophageal eosinophilia pa-
tients in this study. Heartburn, dyspepsia, and reflux were 
less common. In many previous studies, longitudinal furrows 
were most frequently observed endoscopic findings in both 
Asian and Western countries.15,16 We reported that longi-
tudinal furrows were most frequently observed and other typ-
ical findings, like concentric rings, stricture, and white pla-
que, were similar to previous studies. However, esophageal 
eosinophilia with normal endoscopic finding was higher in 
our study (15.8%) than in another study (8.8%).17 This sug-
gests that if esophageal eosinophilia is clinically suspected, 
histopathologic confirmation will be needed, despite normal 
endoscopic finding. In our study, clinicopathologic improve-
ment or endoscopic alteration after treatment were com-
parable to those in other studies, but the ratio of PPI-REE to 
esophageal eosinophilia was higher in our study (77.8%) than 
in other studies.4-6 The clinical and endoscopic findings was 
not distinguishable among those with PPI-REE, EoE, and un-
determined esophageal eosinophilia, similar to other studies.14,17 
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Fig. 1. Treatment outcomes. (A) Initial endoscopic finding was linear furrow, which disappeared at the follow-up endoscopy (B) with improve-
ment of eosinophilia. (C) Initial endoscopic finding was geographic shape furrow, which was maintained or aggravated at follow-up endos-
copy (D) even if, eosinophilia disappeared. (E) Initial endoscopic finding was multiple white plaques with minimal concentric rings. (F) White 
plaques almost disappeared, but concentric rings remained. Eosinophilia disappeared.
We tried an 8 weeks trial of high-dose PPI initially when 
esophageal eosinophilia was confirmed to distinguish EoE 
and PPI-REE. In PPI-REE patients, there are several mecha-
nisms attributed to symptomatic and histologic responses to 
PPI. First, some PPI-REE patients may have gastroesophageal 
reflux disease also, so a suppression of gastric acid by PPI may 
reduce symptoms. Moreover, PPIs have anti-inflammatory ef-
fects by reducing eosinophils by decreasing Th2 cytokine 
stimulated eotaxin-3 mRNA expression and protein secretion 
independent of the effects on acid production.11,17,18  In our 
study, 7 of 9 patients that underwent follow-up endoscopy 
were improved after PPI trial. Their follow-up endoscopic 
changes were diverse, from complete or partial improvement 
to no endoscopic change, but all 7 patients with PPI-REE 
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showed histopathologic and symptomatic improvement. Two 
patients with EoE had normal finding of follow-up endoscopy 
after treatment with inhaled corticosteroid. They all had 
symptomatic improvement, but 1 of 2 patients showed no 
histopathologic improvement.
There are several limitations in this study. First, despite the 
long study period (10 years), only 19 patients were included. 
Furthermore 10 of 19 patients were lost to follow-up. Second, 
the interval time of follow-up endoscopy and treatment dura-
tion were not consistent. Third, in recently published papers 
from expert panels, PPI trial for diagnosis of PPI-REE from EoE 
was not recommended, because phenotypic, molecular, 
mechanistic, and therapeutic features cannot reliably dis-
tinguish PPI-REE from EoE. So they described that PPI trial 
brought more confusion than clarification, and suggested 
PPI-REE as a clinical sub-phenotype of EoE and not a distinct 
entity.1,19 Therefore, in Korea, further, discussion of this con-
troversy may be necessary, through a multicenter and pro-
spective study with long term follow-up.
In conclusion, patients with EoE and PPI-REE in Korea were 
similar in clinicopathologic characteristics and endoscopic 
findings to those reported in other Asian and Western 
countries. However, the proportion of patients with normal 
endoscopic finding of esophageal eosinophilia and the ratio 
of PPI-REE to esophageal eosinophilia were higher in the 
Korean population compared with Western populations. 
Clinicopathologic response of treatment after PPI or steroid 
were satisfactory, but endoscopic improvement were various 
from patient to patient. This suggests that EoE and PPI-REE 
are chronic inflammatory diseases of the esophagus with ir-
reversible change. Therefore, appropriate diagnosis and 
management will be necessary if esophageal eosinophilia is 
suspected.
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